HONG KONG – Pfizer Inc. will bring Basilea Pharmaceutica Ltd.'s novel antifungal medicine to China and other major Asian markets as it works to meet a significant unmet need, one that is a leading cause of death across Asia.
HONG KONG – Astellas Pharma Inc. is exercising its rights in a previous partnership agreement to acquire its R&D collaborator Mitobridge Inc. for $450 million.
HONG KONG – Pfizer Inc. will bring Basilea Pharmaceutica Ltd.'s novel antifungal medicine to China and other major Asian markets as it works to meet a significant unmet need, one that is a leading cause of death across Asia.
HONG KONG – Astellas Pharma Inc. is exercising its rights in a previous partnership agreement to acquire its R&D collaborator Mitobridge Inc. for $450 million.
HONG KONG – AJ Biologics Sdn. Bhd., of Malaysia, recently broke ground on the first vaccine manufacturing facility in the country and is going after innovation in the vaccine space with the new plant.
HONG KONG – Astrazeneca plc has teamed up with the Chinese Future Industry Investment Fund (FIIF) to form a joint venture in China for drug development via an equally owned, stand-alone company named Dizal Pharmaceutical.
HONG KONG – Samsung Bioepis Co. Ltd. has received approval in both South Korea and Europe for its Herceptin biosimilar. Known as Samfenet in South Korea and as Ontruzant in Europe, it marks the first Herceptin biosimilar to be approved by the European Commission.
HONG KONG – AJ Biologics Sdn. Bhd., of Malaysia, recently broke ground on the first vaccine manufacturing facility in the country and is going after innovation in the vaccine space with the new plant.
